65,437 trials
Depressive Disorder
Primary: Change From Baseline in the Hamilton Depression Rating Scale (HAMD17), on Day 14 and 42 — -10.9; -10.8; -10.3; -18.6 Score on scale
Age-associated Cognitive Impairment · Mild Cognitive Impairment (MCI)
Primary: Change From Baseline to 18 Months on Brief Visual Memory Test-Revised, Recall — 19.2; 20.3; 22.4; 22.5 units on a scale — p=0.5
Glaucoma
Primary: Visual Field Mean Deviation — -8.7; -13.3; -13.2; -8.3 dB (decibels)
Acute Kidney Injury
Primary: Change in [TIMP2]*[IGFBP7] Biomarker — 0.015; 0.009 (ng/mL)^2/1000
Healthy
Primary: Time to Reach Maximum Observed Concentration (Tmax) of Fentanyl in Cerebrospinal Fluid (CSF) (1 of 3) — 1.01; 2.00 h
Hematologic Malignancy
Primary: Number of Participants That Experience One Year Relapse Free Survival After Undergoing Hematopoietic Stem Cell Transplant (HSCT) — 5 Participants
Idiopathic Thrombocytopenic Purpura
Primary: Number of Participants With Treatment-Emergent Adverse Events (TEAEs) — 12; 24; 14; 4 Participants
Asthma
Primary: Percentage of Participants With Zero Errors in ELLIPTA DPI Versus GSK MDI and AZ MDI After 28 Days of Use in Each Treatment Phase — 87; 87; 13; NA Percentage of…
Primary Cutaneous Anaplastic Large Cell Lymphoma · Mycosis Fungoides · Cutaneous T-Cell Lymphoma
Primary: Percentage of Participants Achieving an Objective Response That Lasts at Least 4 Months (ORR4) — 54.7; 12.5 percentage of participants — p=<0.001
Acute Lung Injury
Primary: All-cause Mortality at the Time of Pediatric Intensive Care Unit (PICU) Discharge — 15; 6 Participants
Breast Cancer
Primary: Beta of CT Coronal View — 1.75 power-law slope(B)
Bipolar Disorder I or II
Primary: 29 Item Hamilton Rating Scale for Depression (HamD29) — 27.0; 5.8 Hamilton Depression score
Chronic Lymphocytic Leukemia · Prolymphocytic Leukemia · Recurrent Small Lymphocytic Lymphoma
Primary: Maximum-tolerated Dose of Dinaciclib When Given in Combination With Ofatumumab, Defined as a Dose Level Where at Most One of 6 Evaluable Patients Has a Dose Limiting…
Non-Small Cell Lung Cancer
Primary: Progression-Free Survival (PFS) by Investigator Assessment — NA; 11.1 months — p=<0.0001
Diabetes · Diabetes Mellitus, Type 2
Primary: Time From Randomisation to First Occurrence of a MACE, Defined as Cardiovascular Death, Non-fatal Myocardial Infarction, or Non-fatal Stroke — 6.6; 8.9 percentage of…